|
|
|
|
|
|
|
|
|
|
blog
June 23, 2016
Now that a federal biosafety and bioethics committee has approved what would be the first use of the trailblazing genome-editing technology CRISPR-Cas9 in people, the obvious question arises: Could anything go wrong?
The purpose of such a Phase 1 clinical trial is to assess safety, so problems wouldn’t come as a total shock. The fact that the trial in cancer patients (which still needs OKs from the Food and Drug Administration, among others) would be funded by the new cancer institute founded this year by tech mogul Sean Parker adds a wild card. Four potential snafus:....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.